Pfizer CEO and chairman Albert Bourla says that the biopharmaceutical company behind the COVID-19 vaccine could publicly release an antiviral drug designed to treat the coronavirus by the end of 2021.
What are the details?
Bourla on Monday told CNBC’s “Squawk Box” that the drug — called PF-07321332 — is an antiviral drug intended for oral ingestion in COVID-19-positive patients when the illness is first detected. The company is also testing an intravenous option.
The treatment is anticipated to be effective against varying strains of the deadly virus.
Bourla said that the company is zeroing in on the oral option as it ” …